Clinical Study Confirms Effectiveness of CardioSecur® in Pre-Clinical Deployment in Ambulances

CardioSecurThe study "CardioSecur® in the preclinical setting - When time does matter" of the University of Heidelberg confirms the advantages of the mobile ECG in acute cases. This was demonstrated by applying CardioSecur during a period of more than 7 months in ambulances in the area of Heidelberg, Germany.

85.7 % of participating emergency physicians stated that CardioSecur's 4 electrode system was much faster and easier to position in emergency situations and would prefer using it over a conventional 12-lead ECG. Additionally, CardioSecur's 22-leads provide more data (12 leads + V7-9, VR3-VR9) than a standard ECG. The 360° view of the heart enables more comprehensive diagnoses, for example of a posterior myocardial infarction, and can be vital in acute situations. Consequently, the study confirms the efficiency of CardioSecur in time-critical preclinical settings. The system also significantly reduces the risk of electrode misplacement in obese patients and women.

Time plays a crucial role in patients with suspected acute coronary syndrome, as the heart muscle begins to die off only 20 - 60 minutes after the coronary vessel’s blood supply has ceased. During the so-called "golden hour" immediate action is essential to minimize heart muscle damage and optimize patient recovery. Conventional 12 lead ECG systems require 10 electrodes and their placement affects the quality of the ECG significantly. Placement of the 6 chest leads can be particularly complex and time-consuming due to very different body anatomies. CardioSecur’s 4 electrode based 22-lead ECG is faster and easier to position, while also providing more data to detect posterior, lateral and anterior myocardial infarctions.

"Currently, 12-lead ECG systems provide insufficient data to detect posterior myocardial infarctions because in practice the electrodes are rarely placed on the patient's back - even though the ESC guidelines require it," says Felix Brand, founder and CEO of CardioSecur. "The repositioning of the dorsal electrodes also results in an asynchronous ECG (anterior and posterior). CardioSecur is currently the only ECG that meets the cardiological guidelines of the ESC without need for repositioning the electrodes. CardioSecur has already helped to detect posterior myocardial infarctions that were not visible on conventional 12-lead ECGs."

For further information, please visit:
http://www.mobile-ecg.com

About Personal MedSystems GmbH

Personal MedSystems GmbH develops and sells ECG systems and services for private users and healthcare professionals under the name CardioSecur. CardioSecur Active is an innovative, 15-lead, clinical-grade ECG for personal use. In a few seconds, it generates personalized feedback regarding changes in the heart's health and provides a simple recommendation to act regarding whether to see a doctor or not. The entire system consists of a 50g light cable with four electrodes, the complimentary CardioSecur Active App and the user's smartphone or tablet. CardioSecur Pro is the mobile, clinical ECG solution for physicians and medical professionals. CardioSecur Pro operates based upon guidelines from the European Society of Cardiology by providing 22 leads, making a 360° view of the heart possible. It is the only system that thereby recognizes infarctions of the anterior, lateral and posterior walls of the heart.

Most Popular Now

Merck and Tencent Announce Collaboration…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public...

Merck Granted U.S. Patent for Novel Comb…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates...

The European Health Catapult Program for…

Through dedicated sessions, a group of international top-level investors, key healthcare leaders and industry stakeholders work closely together challenging 40+ ambitious startups to optimize their business plan and strengthen their...

Applications Now Open for Pioneering Dig…

The Yorkshire & Humber AHSN (Academic Health Science Network), in partnership with mHabitat, announces that applications for the 2019 Propel@YH digital health accelerator programme are now open. Propel@YH has been...

Flagship Axe the Fax Trust Rolls out Hyb…

Leeds Teaching Hospitals NHS Trust (LTHT), the organisation at the forefront of the national Axe the Fax campaign, is implementing an electronic fax solution to tackle its last remaining machines...

First EU Citizens Using ePrescriptions i…

The first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a...

Boehringer Ingelheim (Canada) Ltd. and I…

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology...

Final Report: Provision of a Market Stud…

The aim of the study is to examine the telemedicine market in Europe and to understand the factors that determine its development. The analysis maps telemedicine applications and solutions, and...

Open Access Drug Development Tools Featu…

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of...

The NHS Long Term Plan: Cracking the Da …

Opinion Article by Prof. Michael Thick, Chief Medical Officer, Chief Clinical Information Officer, IMS MAXIMS Reading the NHS Long Term Plan this week, I had a definite sense of déjà vu...

Big Data Approach Shown to be Effective …

Researchers at Rensselaer Polytechnic Institute who developed a blood test to help diagnose autism spectrum disorder have now successfully applied their distinctive big data-based approach to evaluating possible treatments. The...

Highland Marketing Advisory Board Respon…

The first meeting of Highland Marketing's newly expanded advisory board discussed the NHS Long Term Plan and what will be needed to make it a success. Structural change, leadership, investment...